1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Ward, B.P. Ma, D. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C4 H9 N O2 103.120 n ALPHA-AMINOISOBUTYRIC ACID L-peptide linking C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H9 N O4 147.129 GAMMA-L-GLUTAMIC ACID L-GLUTAMIC ACID L-gamma-peptide, C-delta linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking H2 N 16.023 AMINO GROUP non-polymer C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C16 H32 O2 256.424 PALMITIC ACID non-polymer C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking To be Published 0353 Structural Changes Associated with Peptide Lipidation Broaden Biological Function 10.2210/pdb2m5q/pdb pdb_00002m5q 3446.849 Glucagon 1 syn polymer 147.129 GAMMA-L-GLUTAMIC ACID 2 syn non-polymer 256.424 PALMITIC ACID 1 syn non-polymer no yes H(AIB)QGTFTSDYSKKLD(AIB)RRAQDFVQWLMNT(NH2) HAQGTFTSDYSKKLDARRAQDFVQWLMNTX X polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n database_2 pdbx_database_status struct_conn struct_ref_seq_dif repository Initial release Database references Derived calculations Other 1 0 2013-03-27 1 1 2023-06-14 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data _struct_conn.pdbx_dist_value _struct_conn.pdbx_leaving_atom_flag _struct_conn.ptnr1_auth_comp_id _struct_conn.ptnr1_auth_seq_id _struct_conn.ptnr1_label_atom_id _struct_conn.ptnr1_label_comp_id _struct_conn.ptnr1_label_seq_id _struct_conn.ptnr2_auth_comp_id _struct_conn.ptnr2_auth_seq_id _struct_conn.ptnr2_label_asym_id _struct_conn.ptnr2_label_atom_id _struct_conn.ptnr2_label_comp_id _struct_conn.ptnr2_label_seq_id _struct_ref_seq_dif.details HELIX DETERMINATION METHOD: AUTHOR DETERMINED BMRB Y RCSB 2013-03-04 REL REL REL REL GGL GAMMA-L-GLUTAMIC ACID PLM PALMITIC ACID 9606 human Homo sapiens sample structures with the lowest energy 100 10 2D 1H-1H TOCSY 2D 1H-1H NOESY 0.7 mM 0 5.0 ambient 298 K simulated annealing 1 lowest energy 0.7 mM protein, 95% [U-100% 2H] TFE/5% H2O 95% [U-100% 2H] TFE/5% H2O BRUNGER refinement XPLOR-NIH 600 Varian Varian Uniform NMR System GGL 101 2 GGL GGL 101 X GGL 102 2 GGL GGL 102 X PLM 103 3 PLM PLM 103 X HIS 1 n 1 HIS 1 X AIB 2 n 2 AIB 2 X GLN 3 n 3 GLN 3 X GLY 4 n 4 GLY 4 X THR 5 n 5 THR 5 X PHE 6 n 6 PHE 6 X THR 7 n 7 THR 7 X SER 8 n 8 SER 8 X ASP 9 n 9 ASP 9 X TYR 10 n 10 TYR 10 X SER 11 n 11 SER 11 X LYS 12 n 12 LYS 12 X LYS 13 n 13 LYS 13 X LEU 14 n 14 LEU 14 X ASP 15 n 15 ASP 15 X AIB 16 n 16 AIB 16 X ARG 17 n 17 ARG 17 X ARG 18 n 18 ARG 18 X ALA 19 n 19 ALA 19 X GLN 20 n 20 GLN 20 X ASP 21 n 21 ASP 21 X PHE 22 n 22 PHE 22 X VAL 23 n 23 VAL 23 X GLN 24 n 24 GLN 24 X TRP 25 n 25 TRP 25 X LEU 26 n 26 LEU 26 X MET 27 n 27 MET 27 X ASN 28 n 28 ASN 28 X THR 29 n 29 THR 29 X NH2 30 n 30 NH2 30 X author_defined_assembly 1 monomeric X AIB 2 ALPHA-AMINOISOBUTYRIC ACID A AIB 2 ALA X AIB 16 ALPHA-AMINOISOBUTYRIC ACID A AIB 16 ALA 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 2 X X H2 H HIS AIB 1 2 1.31 6 X X H2 H HIS AIB 1 2 1.30 7 X X O H LYS ARG 13 17 1.60 1 X GLN 3 -53.79 -9.96 1 X THR 7 -103.56 -70.46 1 X ASP 9 -73.09 37.77 1 X TYR 10 -149.40 26.80 1 X LYS 13 -133.07 -75.35 1 X ASP 15 -76.05 45.55 1 X AIB 16 176.54 -22.23 1 X PHE 22 -76.58 -72.62 1 X VAL 23 -55.09 -1.34 2 X AIB 2 64.28 -156.44 2 X GLN 3 53.71 -83.61 2 X THR 7 79.18 -58.79 2 X SER 8 -53.99 -70.88 2 X TYR 10 -67.33 -174.20 2 X SER 11 59.22 4.95 2 X LYS 12 -135.79 -63.22 2 X LYS 13 -85.95 -88.86 2 X ASP 15 -74.72 44.59 2 X AIB 16 178.67 -23.80 2 X ASP 21 -53.92 -8.34 2 X PHE 22 -105.13 -70.09 2 X VAL 23 -55.87 -0.40 3 X AIB 2 -163.66 -14.70 3 X GLN 3 41.52 92.79 3 X SER 8 -41.73 -79.10 3 X TYR 10 -41.91 98.78 3 X SER 11 169.23 -40.00 3 X LYS 12 -116.19 58.91 3 X LYS 13 -171.76 -58.54 3 X AIB 16 176.89 -15.86 3 X GLN 20 -67.90 -70.88 3 X PHE 22 -80.93 -73.40 3 X VAL 23 -54.50 -2.11 3 X MET 27 -95.19 -156.84 3 X ASN 28 59.55 2.80 4 X AIB 2 61.11 125.51 4 X GLN 3 -72.87 45.06 4 X THR 5 52.56 14.60 4 X SER 11 -54.44 -7.88 4 X LYS 13 -44.04 -79.55 4 X ASP 15 -73.89 46.34 4 X AIB 16 177.41 -24.64 4 X ASP 21 -54.55 -7.74 4 X PHE 22 -105.50 -70.21 4 X VAL 23 -55.79 -0.42 4 X ASN 28 -101.10 43.33 5 X GLN 3 63.22 -71.74 5 X PHE 6 58.31 129.34 5 X THR 7 -93.88 -81.64 5 X SER 11 164.07 -42.16 5 X AIB 16 178.10 -41.68 5 X PHE 22 -108.49 -66.26 5 X VAL 23 -58.15 1.96 5 X MET 27 -91.37 -153.95 6 X GLN 3 70.37 -62.94 6 X PHE 6 -168.41 -11.36 6 X SER 8 -49.20 -12.56 6 X TYR 10 -145.42 23.48 6 X LYS 13 -137.45 -80.21 6 X AIB 16 178.02 -51.63 6 X ALA 19 -135.80 -35.52 6 X ASP 21 -53.58 -8.67 6 X PHE 22 -105.53 -69.89 6 X VAL 23 -56.02 -0.32 6 X ASN 28 -95.70 31.35 7 X AIB 2 172.17 -72.32 7 X GLN 3 -50.68 -9.11 7 X THR 7 -41.06 -70.39 7 X SER 8 -73.52 27.69 7 X ASP 9 -158.04 17.50 7 X LYS 12 -145.16 -44.55 7 X LYS 13 -100.26 -90.90 7 X ASP 15 -77.87 45.78 7 X AIB 16 177.87 -50.66 7 X ALA 19 -139.96 -33.42 7 X ASP 21 -56.88 -5.67 7 X PHE 22 -107.31 -71.14 7 X VAL 23 -55.27 -0.83 8 X AIB 2 67.75 -144.46 8 X GLN 3 33.04 49.79 8 X THR 7 -93.95 -67.73 8 X SER 8 -63.44 72.23 8 X ASP 9 165.33 -12.53 8 X LYS 13 -172.57 -45.05 8 X ASP 15 -75.30 22.27 8 X AIB 16 -156.85 -1.58 8 X GLN 20 -70.46 -75.66 8 X PHE 22 -92.11 -72.99 8 X VAL 23 -54.00 -1.93 8 X ASN 28 -97.06 -65.06 9 X GLN 3 -70.30 40.33 9 X LYS 12 -111.08 73.79 9 X LYS 13 -163.25 -52.18 9 X AIB 16 177.07 -30.52 9 X GLN 20 -66.82 -74.41 9 X PHE 22 -76.28 -73.25 9 X VAL 23 -56.91 0.32 10 X THR 7 -43.83 169.56 10 X SER 8 78.13 -20.33 10 X SER 11 80.60 7.54 10 X LYS 13 -103.38 -91.47 10 X ASP 15 -77.30 47.37 10 X AIB 16 -179.67 -17.32 10 X PHE 22 -81.63 -72.39 10 X VAL 23 -55.45 -0.79 Solution structure of lipidated glucagon analog in d-TFE 1 N N 2 N N 2 N N 3 N N X PHE 6 A PHE 6 HELX_P X LEU 14 A LEU 14 5 1 9 X ARG 17 A ARG 17 HELX_P X ASN 28 A ASN 28 1 2 12 covale 1.329 both X HIS 1 A C HIS 1 1_555 X AIB 2 A N AIB 2 1_555 covale 1.328 both X AIB 2 A C AIB 2 1_555 X GLN 3 A N GLN 3 1_555 covale 1.329 one X LYS 13 A NZ LYS 13 1_555 X GGL 101 B CD GGL 1_555 covale 1.329 both X ASP 15 A C ASP 15 1_555 X AIB 16 A N AIB 16 1_555 covale 1.329 both X AIB 16 A C AIB 16 1_555 X ARG 17 A N ARG 17 1_555 covale 1.304 both X THR 29 A C THR 29 1_555 X NH2 30 A N NH2 30 1_555 covale 1.329 both X GGL 101 B N GGL 1_555 X GGL 102 C CD GGL 1_555 covale 1.329 both X GGL 102 C N GGL 1_555 X PLM 103 D C1 PLM 1_555 LIPID BINDING PROTEIN GLUCAGON, DIABETES, OBESITY, LIPIDATED, LIPID BINDING PROTEIN GLUC_HUMAN UNP 1 53 P01275 HSQGTFTSDYSKYLDSRRAQDFVQWLMNT 53 81 2M5Q 1 29 P01275 X 1 1 29 1 SER engineered mutation AIB 2 2M5Q X P01275 UNP 54 2 1 TYR engineered mutation LYS 13 2M5Q X P01275 UNP 65 13 1 SER engineered mutation AIB 16 2M5Q X P01275 UNP 68 16 1 amidation NH2 30 2M5Q X P01275 UNP 30 BINDING SITE FOR LINKED RESIDUES X 101 to 103 Software 3 X ASP 9 A ASP 9 3 1_555 X TYR 10 A TYR 10 3 1_555 X LYS 13 A LYS 13 3 1_555